Stockscreener 앱 받기
13.56
3.94%
-0.515
전일 마감가:
$14.07
열려 있는:
$12.815
하루 거래량:
20.52M
Relative Volume:
2.95
시가총액:
$1.33B
수익:
$2.23B
순이익/손실:
$-248.39M
주가수익비율:
-5.0409
EPS:
-2.69
순현금흐름:
$-697.55M
1주 성능:
-29.69%
1개월 성능:
-32.67%
6개월 성능:
-88.42%
1년 성능:
-90.71%
1일 변동 폭
$12.60
$13.95
1주일 범위
$12.60
$22.86
52주 변동 폭
$12.60
$150.48
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
13.57 | 1.89B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.19 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.00 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.08 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.47 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Sarepta shares cut to $0 at H.C. Wainwright (SRPT:NASDAQ) - Seeking Alpha
Navigating the Crossroads of Innovation and Safety: Assessing Sarepta Therapeutics in the Gene Therapy Landscape - AInvest
Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy - Fierce Biotech
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program - Yahoo Finance
Sarepta Is Worth $0 Amid ‘Unwinnable’ FDA Fight, Analyst Says - Bloomberg.com
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma
Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug - Investopedia
Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA - Investor's Business Daily
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Piper Sandler lowers Sarepta Therapeutics stock price target on Elevidys concerns - Investing.com
Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug - Yahoo Finance
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - TradingView
Sarepta Stock Sinks. How Its Crisis Went From Bad to Worse. - Barron's
Sarepta Therapeutics: Why Is SRPT Stock Crashing? - Forbes
Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - Morningstar
Sarepta Stands Ground Against HHS Request to Stop Elevidys Shipments - BioSpace
Sarepta slides as FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics stock rating reiterated at Hold by TD Cowen - Investing.com
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys - Benzinga
SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline - Newsfile
Sarepta Therapeutics stock price target slashed to $0 by H.C. Wainwright - Investing.com
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT) - StreetInsider
Sarepta extends losses premarket after refusing FDA’s halt request (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at Needham & Company LLC - Defense World
Oppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $41.00 - Defense World
Bank of America Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00 - Defense World
Leerink Partnrs Has Pessimistic Outlook of SRPT Q2 Earnings - Defense World
What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire
Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World
Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News
Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC - Defense World
StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies - Genetic Engineering and Biotechnology News
This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance
Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report
Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com
Sarepta to continue Elevidys shipments despite FDA request to halt - Seeking Alpha
Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest
M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World
Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.17%
자본화:
|
볼륨(24시간):